Inovio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INO Inovio Pharmaceuticals Inc
BAC Bank of America Corp
DGRW WisdomTree U.S. Quality Dividend Growth Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DES WisdomTree U.S. SmallCap Dividend Fund
DEO Diageo PLC
DDF Delaware Investments Dividend and Income Fund
DAL Delta Air Lines Inc
D Dominion Energy Inc
Go

Health Care : Biotechnology | Mid Cap Blend
Company profile

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Premarket

Last Trade
Delayed
$21.24
0.31 (1.48%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$20.93
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
3,468

10-day average volume:
88,421,776
3,468

LAWSUITS FILED AGAINST INO, NCLH and HALL - Jakubowitz Law Pursues Shareholders Claims

7:43 pm ET May 11, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / May 11, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

CONTACT JAKUBOWITZ ABOUT INO:https://claimyourloss.com/securities/inovio-pharmaceuticals-inc-loss-submission-form/?id=6447&from=1

Class Period: February 14, 2020 - March 9, 2020

Lead Plaintiff Deadline: May 12, 2020

According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.

Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH)

CONTACT JAKUBOWITZ ABOUT NCLH:https://claimyourloss.com/securities/norwegian-cruise-line-holdings-ltd-loss-submission-form/?id=6447&from=1

Class Period : February 20, 2020 - March 12, 2020

Lead Plaintiff Deadline: May 11, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was employing sales tactics of providing customers with unproven and/or blatantly false statements about COVID-19 to entice customers to purchase cruises, thus endangering the lives of both their customers and crew members; and (2) as a result, Defendants' statements regarding the Company's business and operations were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Hallmark Financial Services, Inc. (NASDAQ:HALL)

CONTACT JAKUBOWITZ ABOUT HALL:https://claimyourloss.com/securities/hallmark-financial-services-inc-loss-submission-form/?id=6447&from=1

Class Period: March 5, 2019 - March 17, 2020

Lead Plaintiff Deadline: July 6, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal controls over accounting and financial reporting related to reserves for unpaid losses; (2) the Company improperly accounted for reserve for unpaid losses and loss-adjustment expenses related to its Binding Primary Commercial Auto business; (3) as a result, Hallmark Financial would be forced to report a $63.8 million loss development for prior underwriting years; (4) as a result, Hallmark Financial would exit from its Binding Primary Commercial Auto business; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com: https://www.accesswire.com/589429/LAWSUITS-FILED-AGAINST-INO-NCLH-and-HALL--Jakubowitz-Law-Pursues-Shareholders-Claims

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.